Gennex Lab. (531739)
Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹13.87 |
| Market Cap | ₹315.47 Cr |
| P/E Ratio | 15.6 |
| ROCE | 13.01% |
| ROE | 8.17% |
| Dividend Yield | 0% |
| Profit Growth | 18.01% |
| Debt/Equity | — |
| Sales Growth | 7.37% |
| 52-Week Range | ₹7.05 — ₹17.25 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹7.54 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Whenever I look at a pharmaceutical company, I ask two questions: does it have a defensive moat, and can it compound capital at attractive rates? Gennex Lab fails my moat test from the numbers alone. It is a ₹315 Cr microcap with a P/E of 15.60 and a P/B of 1.84. A book value of ₹7.54 means the market expects some improvement. But with an ROE of 8.17%, the business is not generating exceptional returns on shareholder capital. ROCE at 13.01% is respectable, yet not the kind of franchise I can sleep on.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer